Nuvalent (NASDAQ:NUVL) Lowered to Hold Rating by Wells Fargo & Company

Wells Fargo & Company downgraded shares of Nuvalent (NASDAQ:NUVL) from a strong-buy rating to a hold rating in a research note issued to investors on Tuesday,Zacks.com reports.

NUVL has been the topic of several other reports. Sanford C. Bernstein assumed coverage on shares of Nuvalent in a research report on Thursday, May 21st. They set an “outperform” rating and a $189.00 target price on the stock. Stifel Nicolaus set a $124.00 target price on shares of Nuvalent in a research report on Tuesday. HC Wainwright downgraded shares of Nuvalent from a “buy” rating to a “neutral” rating and set a $124.00 target price on the stock. in a research report on Tuesday. UBS Group set a $124.00 price target on shares of Nuvalent in a research report on Wednesday. Finally, Raymond James Financial downgraded shares of Nuvalent from an “outperform” rating to a “market perform” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.27.

Nuvalent Price Performance

NASDAQ:NUVL opened at $123.25 on Tuesday. The firm’s 50 day simple moving average is $102.91 and its 200 day simple moving average is $103.08. Nuvalent has a one year low of $71.13 and a one year high of $123.62. The company has a market cap of $9.74 billion, a PE ratio of -20.34 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period last year, the business posted ($1.18) EPS. Equities research analysts expect that Nuvalent will post -5.74 EPS for the current year.

Insider Activity

In other news, insider Henry E. Pelish sold 3,093 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $104.48, for a total value of $323,156.64. Following the transaction, the insider owned 65,604 shares in the company, valued at approximately $6,854,305.92. The trade was a 4.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James Richard Porter sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the transaction, the chief executive officer owned 324,879 shares in the company, valued at $33,036,945.51. This trade represents a 8.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 96,953 shares of company stock worth $9,956,364 over the last quarter. Company insiders own 5.02% of the company’s stock.

Institutional Trading of Nuvalent

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC increased its stake in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares in the last quarter. Kennedy Capital Management LLC increased its stake in shares of Nuvalent by 1.5% in the 4th quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company’s stock valued at $1,100,000 after acquiring an additional 163 shares in the last quarter. US Bancorp DE increased its stake in shares of Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after acquiring an additional 188 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after acquiring an additional 195 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of Nuvalent by 7.7% in the 3rd quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock valued at $285,000 after acquiring an additional 234 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK announced a definitive all-cash acquisition of Nuvalent for about $10.6 billion, giving shareholders $124 per share and sparking a takeover-driven rerating. Reuters article
• Positive Sentiment: The deal adds Nuvalent’s late-stage lung cancer pipeline to GSK’s oncology business, which likely helped justify the premium and support investor enthusiasm. WSJ article
• Positive Sentiment: Options activity surged sharply, suggesting traders were positioning for further upside and volatility around the buyout news. Quiver Quant article
• Neutral Sentiment: Several analysts adjusted ratings and price targets to around the deal value, which reflects the market now focusing more on the acquisition price than standalone fundamentals. Benzinga article
• Negative Sentiment: Law firms and investor groups launched investigations into whether shareholders are receiving a fair price, adding a layer of deal-related uncertainty. GlobeNewswire article
• Negative Sentiment: Recent analyst downgrades to neutral could temper expectations for any upside beyond the takeover price. Benzinga article

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.